NEUTRAL: For the coming year, we believe the share’s valuation will reflect its cash balance of SEK 5 per share. Towards late 2020, we see a range between SEK 12-14 per share suggesting 153-195% upside to the current share price. Towards late 2021, we see a range between SEK 20-24 per share, suggesting 321-405% upside.
First clinical stage read-out in late 2021 instead of early 2020
AlzeCure’s lead product asset, ACD855, started clinical development in late 2018 with the ambition to generate first clinical trials by early 2020. However, early human exposure with the tablet product demonstrated that the concentration of the substance would require significantly longer dosing intervals than once daily, so the future development of the substance will now only be pursued with a formulation targeting ophthalmologic disorders. Instead, AlzeCure will move another substance, ACD856, that belongs to the same NeuroRestore substance class, into clinical stage development towards late 2019, targeting results towards H2 2021. The single and multiple ascending dose parts of the trials with ACD856 will have around 60 participants in each.
Marketing material commissioned by AlzeCure Pharma